Brief: Sight Sciences Q2 Revenue USD 19.6 Million Vs. IBES Estimate USD 18.2 Million

Sight Sciences

07/08/2025 21:05

Overview

Sight Sciences Q2 revenue falls 8% yr/yr but beats analyst expectations, per LSEG data

Operating expenses decreased 9% yr/yr

Company raises full-year revenue guidance, indicating confidence in future performance

Outlook

Sight Sciences raises full-year 2025 revenue guidance to $72.0 mln-$76.0 mln

Company reaffirms 2025 adjusted operating expenses guidance at $101.0 mln-$105.0 mln

Sight Sciences expects tariff costs to decrease to $1.0 mln-$1.5 mln in 2025

Company anticipates 5%-10% revenue decline for full-year 2025 compared to 2024

Result Drivers

MEDICARE RESTRICTIONS - Decline in Surgical Glaucoma revenue attributed to Medicare coverage restrictions on MIGS procedures with cataract surgery

ORDERING ACCOUNTS - Increase in Surgical Glaucoma ordering accounts to an all-time high, partially offsetting revenue decline

DRY EYE FOCUS - Decrease in Dry Eye revenue due to focus on achieving reimbursed market access for TearCare procedures

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$19.60 mln
$18.20 mln (6 Analysts)
Q2 Net Income
-$11.90 mln
Q2 Gross Margin
85.0%
Q2 Gross Profit
$16.60 mln
Q2 Operating Expenses
$28.30 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Sight Sciences Inc is $4.00, about 8% above its August 6 closing price of $3.68

Press Release: ID:nGNX3ztmbH

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)